Abstract
In the original publication of the article, the second author name has been misspelled.
Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
R B Verheijen
,
E L Swart
,
J H Beijnen
,
J H M Schellens
,
A D R Huitema
,
N Steeghs
More about this publication
Cancer chemotherapy and pharmacology
Volume
86
Issue nr.
1
Pages
163
Publication date
01-07-2020
Full text links
Publisher website (DOI)
10.1007/s00280-020-04090-4
Europe PubMed Central
32524189
Pubmed
32524189